Roche highly anticipated cancer immunotherapy fails in first late-stage trial Ruchika Sharma3 April 2022 4:00 AM GMTTiragolumab works by selectively binding itself to TIGIT, a receptor found on immune system cells that normally serves to prevent an immune attack...
Roche gets USFDA nod to VENTANA PD-L1 Assay as companion test for lung cancer Ruchika Sharma24 Oct 2021 5:30 AM GMTBasel: Roche has recently announced U.S. Food and Drug Administration (USFDA) approval of the VENTANA PD-L1 (SP263) Assay in non- small cell lung...
Roche gets USFDA okay for cancer treatment Tecentriq Ruchika Sharma16 Oct 2021 11:00 AM GMTBasel: Roche has recently announced that the US Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) as adjuvant treatment,...
Roche withdraws Tecentriq for treating type of breast cancer in US Ruchika Sharma28 Aug 2021 4:30 AM GMTNew Delhi: Roche Holding AG has decided to withdraw its immunotherapy Tecentriq as a treatment for a type of breast cancer in the United States, the...
Roche Tecentriq Pivotal Phase III data shows hope for cancer patients Ruchika Sharma20 May 2021 5:30 AM GMTBasel: Roche today announced interim results from the Phase III IMpower010 study, showing for the first time that treatment with Tecentriq...
Roche Tecentriq, Avastin combo gets positive CHMP opinion for liver cancer Ruchika Sharma20 Sep 2020 4:30 AM GMTBasel: Roche has recently announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended...
FDA nod to Roche's Tecentriq plus Cotellic and Zelboraf in advanced melanoma Ruchika Sharma3 Aug 2020 4:00 AM GMTBasel: Roche has announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab) plus Cotellic® (cobimetinib)...
Roche gets USFDA nod to Tecentriq-Avastin combination to treat liver cancer Ruchika Sharma1 Jun 2020 8:18 AM GMTZurich: Swiss drugmaker Roche said on Friday that the U.S. Food and Drug Administration (FDA) approved its immunotherapy Tecentriq in combination with...
